Vilin Bio Med Ltd.
NNSE:VILINBIO52.00
INR
+1.40
(+2.77%)
ISIN
INE0L4V01013
Return %
Stock
S&P 500
1Y
92.59
14.20
3Y
135.29
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Yadamakanti Madhu S. Reddy
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Sagar Co-op Housing Society Ltd Khairatabad TS India 500034
- IPO Date
- Jun 30, 2023
- Website
- vilinbio.com
- Similar Companies
- Business
- Vilin Bio Med Ltd is an ISO-9001-2008 and GMP certified manufacturer of pharmaceutical formulations, specializing in beta-lactam and non-beta-lactam products including oral liquids such as syrups, suspensions and dry powders; tablets and capsules; external preparations; sachets; and nutritional supplements encompassing multi-vitamins, minerals and amino acids. The company operates across key therapeutic segments including cardiovascular, musculoskeletal, antibiotics, central nervous system, gastrointestinal, respiratory, anti-diabetic, anti-allergic and genito-urinary tract drugs, selling its products in bulk to pharmaceutical manufacturers, marketers and traders without branding its own products. It maintains a vertically integrated approach covering active pharmaceutical ingredient development, formulation, testing, marketing, distribution and market vigilance, supported by in-house research and development focused on generic drugs, novel formulations and advanced drug delivery systems. Incorporated in 2005 and headquartered in Roorkee, Uttarakhand, India, with an original registered office in Hyderabad, Telangana, Vilin Bio Med Ltd employs over 600 professionals and targets regulated export markets such as the USA, UK, Europe, Canada and South America alongside domestic operations. In recent developments, the company welcomed new promoters in 2021 and appointed seasoned professionals to its board in 2022 to strengthen management and corporate governance. It entered a strategic collaboration agreement with Ballard Partners, a leading US government relations and public affairs firm, to support global expansion. Additionally, in 2025, an open offer was launched to acquire 26% of shares at ₹23.40 per share, with tendering from September 1 to 15, alongside the 19th annual general meeting in August 2025 where financial accounts were adopted and Madhusudhan Reddy was appointed managing director.